Natera Broadens Oncology Footprint With Trial Partnerships, Japanese Approval, and Upgraded Analyst Targets

Natera advanced Signatera trials, won Japanese approval for bladder cancer, and saw Citigroup and Barclays lift price targets after ASTRO data.

Natera is pressing ahead on two fronts at once — deepening its clinical trial pipeline while extending the commercial reach of its Signatera tumor-monitoring test into new geographies. The US diagnostics company unveiled a collaboration with TransCode Therapeutics for a Phase 2a colorectal cancer study evaluating the drug candidate TTX-MC138, a move that ties molecular residual disease detection directly to therapeutic development. The logic behind such tie-ups is straightforward: pairing Signatera's molecular profiling with novel agents allows researchers to track treatment response more precisely throughout the trial.

That partnership sits alongside a broader study push. On October 5, Natera and the Alliance Foundation Trials announced the global Phase III AFT-70 NAVIGATE trial, conducted with Genentech, which will test a Signatera-guided treatment strategy in early breast cancer. More than 2,000 patients are to be enrolled across roughly 200 sites. Two days later came word that the first patients had been dosed in an NYU Langone Health-initiated study examining therapy escalation in advanced or metastatic melanoma for patients who tested positive on Signatera after first-line treatment.

Congress Data Draw Attention

The company's clinical momentum was on full display at the ASTRO annual meeting on October 6, where Natera presented fresh data on Signatera spanning gastrointestinal and gynecological cancers. Four oral presentations anchored the session, covering risk stratification and therapy-response monitoring. In a rectal cancer study, the test demonstrated 100% sensitivity for local tumor growth or recurrence. A separate study on vulvovaginal carcinomas showed Signatera catching tumor recurrence early, achieving a median lead time of 117 days ahead of detection by imaging — a result with clear practical value for radiation oncologists managing these patients.

Analysts Lift Price Targets

Those data releases prompted several research houses to revise their outlooks sharply higher. Albert Hu of Citigroup adjusted his forecast on October 6, keeping a "Buy" rating while raising his price target from $365 to $480. Barclays followed a day later, with analyst Luke Sergott reaffirming an "Overweight" call and lifting his target from $340 to $475. Both analysts point to clinical validation as a key driver of further market penetration.

Japan Approval Opens New Market

Geographic expansion is advancing in parallel. On September 23, Signatera received approval from Japan's PMDA for patients with muscle-invasive bladder cancer, with a market launch planned for the first half of 2027. The clearance opens additional potential beyond Natera's home market and should help cement its competitive position as the test becomes more established in routine clinical practice.

Underlying demand remains strong. Oncology test volumes climbed 57% year over year, and total company revenue rose roughly 38% compared with the prior-year period. Market watchers expect sustained momentum in residual disease diagnostics, with analysts projecting revenue growth above 40% in that segment for the current year. In 2025, sales in the segment already approached the $1 billion mark.

Digital Platform and Balance Sheet

Supporting the operating business is an expanding digital offering. A dedicated patient portal gives users secure, encrypted access to findings and the processing status of their tests, meeting US health data privacy standards. The system covers genetic cancer risk as well as prenatal diagnostics analyses.

Financially, the company retains ample liquidity for further expansion, with a debt-to-equity ratio of 0.04. That funding position provides room for research spending and international commercialization while keeping profitability in focus.

The stock ended Monday's session at €356.60. Since the start of the year, the shares have gained 81%, trading near their 52-week high of €389.40 set on October 6. In today's trading, the stock was quoted at €355.40.